No random market condition or individual product launch could create, nor sustain, the type of continual growth we have experienced.
Columbia, SC (PRWEB) August 27, 2012
In a year already defined by record sales and distribution, BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of specialty biotherapeutics, announced that the company’s forecast for calendar year Q3 exceeds that of the previous two quarters of 2012.
“No random market condition or individual product launch could create, nor sustain, the type of continual growth we have experienced,” stated Richard Gaton, Co-Founder and Co-President of BDI. “The fact that our success has remained consistent and predictable is a testament to the longevity and experience of our management and senior management staff. With more than 150 years of collective industry know-how, our tenured team has demonstrated, time and again, that it has the knowledge and resources to successfully navigate the minefield that is the U.S. healthcare marketplace.”
“We are in a league of our own when it comes to insight into institutional history and market trends. Our vast experience in specialty pharmacy distribution and over 17 years of commitment provides a balanced approach toward initiatives and growth opportunities,” stated Edward Stiefel, Co-Founder and Co-President of BDI. “This level of production sets the table for both a robust fourth quarter and continued optimism regarding the corporation’s growth into 2013.”
About BDI Pharma, Inc.
Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for comprehensive reimbursement services -- bdiaccess.com; specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; resources for flu vaccine and general vaccines/immunologics -- securivax.com; and purchasing programs -- securigam.com and qoreprogram.com round out a family of solutions tailored to the needs of the healthcare community at large.
BDI Pharma’s portfolio includes IVIG, branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.